CanSino Biologics Inc. (the “Company,” stock code: 6185) will convene its 2025 Second Extraordinary General Meeting (EGM) on November 27, 2025, at 2:00 p.m. This meeting will be held at No.1, Yuebin Hall, 2nd Floor, Hyatt Regency Tianjin East in Tianjin, the People’s Republic of China.

The EGM will consider several special resolutions, including the proposed cancellation of the Board of Supervisors, updates to the Articles of Association, and revisions to related procedural rules. Ordinary resolutions cover amendments to corporate governance policies, including management of raised funds, related party transactions, external guarantees, external investments, and terms of reference for Independent Non-executive Directors. Additionally, shareholders will review a proposal on utilizing reserves to offset the Company’s losses.

A cumulative voting system will be employed in electing two independent non-executive Director candidates: Mr. Man Cho and Ms. Xuefeng Ji. Shareholders may distribute their votes for the proposed candidates according to the total number of voting rights they hold.

Holders of H shares wishing to appoint a proxy to attend and vote at the EGM must submit the relevant forms and documents to the Company’s H share registrar, Computershare Hong Kong Investor Services Limited, no later than 24 hours before the meeting. Shareholders retain the right to attend and vote in person if they choose. All references to dates and times follow Hong Kong standards.